The James Cancer Network Affiliation

Dayton Physicians—Hematology and Medical Oncology and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute’s (OSUCCC - James) The James Cancer Network have entered into an Affiliation Agreement to establish a relationship between to provide oncology services in Butler, Darke, Miami, Montgomery, and Warren Counties.

By bringing together the best of academic medicine, cancer expertise and community health care in Ohio, the OSUCCC – James and Dayton Physicians- Hematology and Medical Oncology will be uniquely positioned to make a difference in the health of our community and beyond.

The OSUCCC – James is the only cancer program in the United States that features a National Cancer Institute (NCI)–designated comprehensive cancer center aligned with a nationally ranked academic medical center and a free-standing cancer hospital on the campus of one of the country’s largest public universities.

  • With more than 200 oncologists, each of whom specialize in just one type of cancer, the OSUCCC – James offers expert sub-specialization, which leads to more productive integration with cancer research and, ultimately, to better outcomes.

Through the affiliation, and the OSUCCC – James will work together to enhance and expand the scope of oncology care provided throughout the region by developing and collaborative oncological health care delivery system that will provide high-quality, cost-effective cancer care services to all patients and families.

  • To build upon Dayton Physicians- Hematology and Medical Oncology offering of cancer treatments and clinical research trials.
  • Share best practices to ensure greater access to cost-effective, best-practice oncology services.
  • Develop a more robust network of local and regional oncology providers by offering enhanced access to services, education, and operational resources.
  • Collaborate on population health and/or research integration.
  • Maintain a continuum of care within our region with seamless access to the OSUCCC – James’ highly specialized, full spectrum of providers as needed.

This collaboration will provide meaningful benefits to Dayton Physicians—Hematology and Medical Oncology, the OSUCCC – James and the communities we collectively serve.

  • Our communities will benefit from optimized coordination of care, enhanced communication, and an enriched patient experience across all points of care.

This affiliation will provide Dayton Physicians—Hematology and Medical Oncology and patients access to the expertise and specialists at the OSUCCC – James as an affiliate of The James Cancer Network allowing patients to stay close to home during treatment to be near their loved ones and support system.

Affiliations help extend cancer expertise to people in other areas of the state as well as increase research and education opportunities.

Yes, Dayton Physicians—Hematology and Medical Oncology will report outcomes to OSUCCC – James as part of its ongoing auditing and program compliance process. This will help ensure that rigorous standards for patient continues to be met across cancer services.

Yes, The OSUCCC – James has more than 500 open clinical trials at any given time, with some of the world’s latest discoveries available to clinical trial patients. In fact, patients will have access to more cancer clinical trials in our region, as well as access to some of the most advanced, targeted treatments and drugs available.

Cancer Care will continue to be provided by Dayton Physicians—Hematology and Medical Oncology cancer specialist, right here close to home. Dayton Physicians—Hematology and Medical Oncology also supports enhanced access to OSUCCC – James for qualified patients whose care cannot be provided locally.  

Patients will benefit from optimized coordination of care, enhanced communication, and an enriched patient experience across all points of care. Partnerships are vital to helping provide effective treatment to people with cancer and to reduce the incidence of cancer.

This affiliation will provide access to expert sub-specialization, which leads to more productive integration with cancer research and, ultimately, to better outcomes.